LUND, SWEDEN / ACCESS Newswire / July 1, 2025 / Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumor-directed immunotherapies, today announced that ...
LUND, SE / ACCESS Newswire / January 9, 2026 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today ...
LUND, SE / ACCESS Newswire / September 22, 2025 / Alligator Bioscience (STO:ATORX)(Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody ...
Delineation of immunotherapeutic predictive versus prognostic transcriptional programs to identify SLC22A5-centric carnitine metabolism-driven resistance to anti-PD-L1 treatment in advanced ...
"The OPTIMIZE-1 program continues to deliver compelling data supporting the potential of mitazalimab in metastatic pancreatic cancer," said Søren Bregenholt, CEO of Alligator Bioscience . "ASCO GI is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results